Researchers at the Paul-Ehrlich-Institut (PEI), in cooperation with the Philipps-Universität Marburg, used the "recombinant measles vaccine virus" vaccine platform to test vaccine candidates against the dangerous avian H7N9 influenza virus in an animal model. Vectored vaccines with a blueprint of haemagglutinin (H7) or neuraminidase (N9) induced specific antibodies in mice that could effectively inhibit H7N9 influenza viruses. H7-specific T cells were still detected in the animals two years after vaccination.